Industry Newscrisprgene editingintelliaearnings
Intellia Reports Q4 2025 Financial Results
5.9
Intellia Therapeutics on February 26 announced fiscal Q4 and full-year 2025 results, reporting $605.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025, down from $861.7 million a year earlier. Management said the cash runway extends into the second half of 2027 and through lonvo‑z’s anticipated U.S. commercial launch for HAE, while collaboration revenue rose to $23.0 million from $12.9 million.
Key Points
- 1Reports cash position of $605.1M as of Dec 31, 2025, down from $861.7M
- 2Cites funding runway into H2 2027 and through lonvo‑z U.S. commercial launch, reducing near-term financing risk
- 3Shows growing partnership revenue: $23.0M driven by SparingVision termination and increased Regeneron reimbursements
Scoring Rationale
Company-confirmed financial and runway details support credibility, but limited novelty and narrow company scope reduce broader impact.
Sources
Public references used for this report.
Practice with real Telecom & ISP data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Residential CustomersEasyUnlimited Fiber Plans 500Mbps+MediumCustomer Churn Risk AssessmentHard
250 free problems · No credit card
See all Telecom & ISP problems
